SCHEMBL9958076

SCHEMBL9958076

Cc1cc(C)cc(-c2cc(-c3cc(C)cc(C)c3)nc(-c3c[c]ccc3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.39
KMT2A Q03164 8/20 0.39
MAPT P10636 8/20 0.39
ALDH1A1 P00352 5/20 0.39
HPGD P15428 4/20 0.39
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 5/20 0.37
LMNA P02545 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
TSHR P16473 1/20 0.36
ATM Q13315 1/20 0.36
IDO1 P14902 1/20 0.36
METAP2 P50579 1/20 0.36
NTSR1 P30989 1/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9957875 0.87 MEN1 (0.51) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL9957555 0.82 MEN1 (0.52) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL2750488 0.80 RXRA (0.35) ADORA2AADORA1IDO1METAP2
SCHEMBL9957627 0.79 LMNA (0.46) MEN1KMT2AMAPTHPGDRAB9A
SCHEMBL4546904 0.78 MEN1 (0.60) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL4714992 0.78 KDM4E (0.36) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL4546901 0.78 MEN1 (0.42) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL18267903 0.77 MEN1 (0.63) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL20251432 0.77 MEN1 (0.58) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL9957880 0.75 CYP1A1 (0.53) MEN1KMT2AMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624193-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2017-04-18 US disclosed
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT TOSOH CORPORATION (JP) 2015-11-19 US disclosed
US-9120773-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2015-09-01 US disclosed
EP-2818462-A1 Cyclic azine derivatives, processes for producing these, and organic electrolumiscent element containing these as component TOSOH CORPORATION (JP) 2014-12-31 EP disclosed
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT SAGAMI CHEMICAL RESEARCH INSTITUTE, (JP) 2012-08-23 US disclosed
EP-2468731-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT Tosoh Corporation (JP) 2012-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 MEN1 405/4885KMT2A 3592/4885MAPT 4430/4885
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 MEN1 405/4885KMT2A 3592/4885MAPT 4430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.